n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, August 25th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Almost Never Films, Inc. (HLWD)

MarketWatch, YCharts, The Street, and Marketbeat reported on Almost Never Films, Inc. (HLWD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Almost Never Films, Inc. is an independent film company listed on the OTC Markets. The Company’s concentration is on film production and production related services in connection with production costs in the $5.0 million to $50.0 million range. Its business is to enable relationships between creative talent and companies who produce, finance, and also distribute motion pictures. Almost Never Films has its headquarters in Los Angeles, California.

The Company’s intention is to create, acquire, or license rights to materials upon which it believes motion pictures can be based. Mr. Danny Chan is the Chief Executive Officer (CEO) of Almost Never Films.

Furthermore, he is a Managing Director of Iconic Private Equity Partners, based in Hong Kong. Mr. Chan has spent greater than 11 years investing and advising Greater China companies.

Almost Never Films and Saisam Entertainment are partnering to develop and produce the motion picture project "Love Is Not Easy." Danny Chan, Frank Gillen, and Brian Hooks, President of Saisam Entertainment, will serve as lead producers of the film. In addition, Brian Hooks will also be engaged as the writer and director of the movie.

Saisam Entertainment will contribute its development and producing services and the original screenplay. Almost Never Films will make financial contributions and participate in the development and production process to make the movie a box office success.

In June of this year, Almost Never Films announced that it has provided a portion of bridge financing by way of The Money Pool and Blue Rider San Juan for the feature film “Ana.” The film stars Dafne Keen who earlier appeared in “Logan” with Hugh Jackman.

In addition, in June, Almost Never Films announced that it has agreed to provide a portion of Bridge financing through The Money Pool and Blue Rider San Juan, for the motion picture “Speed Kills.” The movie will be directed by John Luessenhop. He previously directed Texas Chainsaw 3D and Takers. “Speed Kills” follows the life of speedboat racing champion Don Aronow played by John Travolta.

Almost Never Films, Inc. (HLWD), closed Friday's trading session at $0.0579, up 37.86%, on 1,500 volume with 1 trade. The average volume for the last 60 days is 49,604 and the stock's 52-week low/high is $0.01/$0.10.

Corix Bioscience, Inc. (CXBS)

OTC Markets and InvestorsHub reported on Corix Bioscience, Inc. (CXBS), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Corix Bioscience, Inc. is a next generation tissue cell culture to pharmaceutical grade cannabinoid oil (CBD) manufacturer. The Company is the developer of proprietary cannabis and industrial hemp strains utilizing tissue cell cultures to propagate living plants. Corix has plans to patent the strains to be used in the pharmaceutical medical industries. Corix Bioscience is based in Phoenix, Arizona. Its laboratory and processing facility is in Carson City, Nevada, and fields for growing the plants are in Genoa, Nevada.

Corix’s mission is to create clean and consistent products in medical grade facilities. At present, it is looking at expanding its mark into Washington, Oregon, California, and Arizona. The Company is developing brand named products to be released early next year. Its team has more than five decades of experience in cultivating and extracting CBD and THCV oils from the industrial hemp plant. Cannabidiol (CBD) is one of at least 113 active cannabinoids identified in cannabis.

Corix Bioscience’s methods allow it to create and breed new and existing plant strains from tissue cells free of any pathogens or disease. It grows these plants to maturity and extract the oils that are the "medicine" portion of the plant.

The Company’s location is on the Washoe Tribal Allotment in Minden, Nevada. Corix has secured a 25-year land lease with the Tribe family to cultivate and process the CBD and THCV oil.

This facility will be in the middle of a major corridor for product grown in Oregon, Northern California, as well as Nevada. Corix Bioscience is already permitted to grow here. The Company has a number of other grows in a 25-mile radius and Southern Nevada.

Earlier this month, Corix Bioscience announced that the Company will move its tissue cell culture and research divisions into a new 10,122 square foot laboratory in Carson City, Nevada on a three-year lease. The lease began on August 1, 2017. The move will enable Corix Bioscience to produce greater than 3 million plantlets in the immediate future. It will set the Company up to double that in the second full year. The new laboratory will be the first known tissue culture facility centered exclusively on the hemp and cannabis market.

In addition, this month, Corix Bioscience announced that it signed an agreement with Positively Green Organics LLC for the resale of up to 22,000 pounds of industrial hemp monthly. Positively Green Organics (PGO) grows industrial hemp on a 160-acre plot of land just south of Carson City, Nevada to produce CBD oil. Of its 160 acres, Corix Bioscience plans to sell up to 22,000 pounds of hemp from 150 acres of PGO's harvest monthly.

Corix Bioscience, Inc. (CXBS), closed Friday's trading session at $0.90, up 28.57%, on 1,022 volume with 3 trades. The average volume for the last 60 days is 288 and the stock's 52-week low/high is $0.31/$2.30.

Foothills Exploration, Inc. (FTXP)

MarketWired, OTC Markets, and InvestorsHub reported on Foothills Exploration, Inc. (FTXP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Foothills Exploration, Inc., through its wholly-owned subsidiary, Foothills Petroleum, Inc. (a Nevada corporation), is an early stage independent oil and gas exploration and production company. It involves in the acquisition and development of oil and gas properties in the Rockies. The Company’s goal is to acquire dislocated and underdeveloped oil and gas assets and maximize those assets.  Foothills Exploration is headquartered in Denver, Colorado.

The Company’s strategy is to build a balanced portfolio of E&P assets through concentrating on acquiring producing and developmental properties in the Rockies and focusing on the generation of high-impact oil and gas exploration projects. Foothills Exploration’s goal is to build a land bank of more than 200,000 acres of proven, probable, and prospective reserves.

Currently, Foothills Exploration holds 41,181 acres in the Greater Green River Basin in Wyoming. Its Springs Prospect consists of 38,120 contiguous acres. This is a multiple objective oil resource play in the Greater Green River Basin.

Moreover, the Company has a 35 percent Working Interest (WI) in the Ladysmith Anticline prospect. This prospect is in Fremont County, Wyoming. Ladysmith Anticline in entirety amounts to 3,061 acres. Its location is between the Great Divide/Greater Green River Basin and the Wind River Basin.

Foothills also has its PawPaw Project. The Pawpaw project is a 3-D seismic defined prospect. It covers 4,467 acres and is a direct analog to the highly productive Tensleep Formation “Enigma” Field positioned two miles south.

The Company also has its Ironwood Project. The Ironwood Project is a 6,115-acre up dip field extension play.  The adjacent “Cotton Creek” Field produced about 67 million barrels of oil (MMBO) and 68 billion cubic feet of gas (BCFG), chiefly from the Phosphoria Formation. 

Foothills Exploration announced in February 2017 that since acquiring Tiger Energy Partners International on December 30, 2016, Foothills has successfully reworked two wells in its Duck Creek project obtaining production from the Green River formation.

Regarding the Duck Creek Area – Natural Buttes Field, Foothills Exploration plans to re-enter two wells in September in the Duck Creek region situated in Uintah County, Utah, in the Natural Buttes field.  The Duck Creek wells recently had a third-party engineering report completed. The Report calculated a total PV-10 value of $707,000 of Proved Developed Producing and Proved Developed Non-Producing reserves.

Concerning the Altamont- Bluebell and Brundage Canyon areas, a third-party reserve report was conducted on certain properties, which were acquired via the Tiger Energy Partners International acquisition.  According to this Report, the properties have roughly 5.4 million barrels of Proved Undeveloped Reserves.  The well depths range from 5,500 feet in the Brundage Canyon area to roughly 18,000 feet in the Altamont-Bluebell area.

Foothills Exploration, Inc. (FTXP), closed Friday's trading session at $0.50, up 5.71%, on 15,100 volume with 7 trades. The average volume for the last 60 days is 8,460 and the stock's 52-week low/high is $0.45/$2.38.

Dakota Territory Resource Corp. (DTRC)

OTC Markets Group, Innovative Marketing, and UltimatePennyStock reported earlier on Dakota Territory Resource Corp. (DTRC), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Dakota Territory Resource Corp.’s emphasis is on the acquisition and responsible exploration and development of high caliber gold properties in the Black Hills of South Dakota. The Company maintains 100 percent ownership of three mineral properties. These include the Blind Gold, City Creek, and Homestake Paleoplacer Properties. All of these are in the heart of the Homestake District. Dakota Territory Resource is based in Reno, Nevada and the Company lists on the OTC Markets.

The Blind Gold Property is Dakota’s flagship property. It is a target for Tertiary-aged and Iron-formation gold mineralization. The Blind Gold Property is around four miles northwest and on structural trend with the historic Homestake Gold Mine. The Homestake Gold Mine produced roughly 40 million ounces of gold through its 125-year production history. It is the largest iron-formation-hosted gold deposit in the world.

In March of last year, Dakota Territory Resource announced that its intention is to continue its sampling program along trend of the zone of high grade gold mineralization identified by the first pass surface sampling program conducted on its 100 percent owned Blind Gold Property. The program identified a zone of high-grade gold mineralization in the Mississippian-age Pahasapa Limestone on the surface, with a peak gold assay value of 9.44 grams per tonne. The Company is preparing for drilling in the Homestake Gold District of South Dakota.

Its City Creek Property is a target for Homestake iron-formation gold mineralization. City Creek consists of 21 unpatented lode mining claims located one-mile northeast of the Homestake Open Cut and one-mile northwest of the City of Deadwood.

The Homestake Paleoplacer Property consists of 13 unpatented lode mining claims positioned one-mile north of the Homestake Open Cut. Dakota Territory Resource based the acquisition of its Black Hills property position on more than 44 years of combined mining and exploration experience in the Homestake District.

This past April, Dakota Territory Resource announced that it entered into agreements with Trucano Novelty, Inc. to acquire a combination of surface and mineral title to 284 acres located in the Homestake District of the Northern Black Hills of South Dakota. Dakota’s property acquisition is consistent with its business development strategy of expanding its high quality mining interests within the Homestake District. The Company now holds approximately 3,341 acres in the core of the district.

In May, Dakota Territory Resource announced that its research of historic data identified high grade gold mineralization under Dakota Territory's recently acquired property at Maitland. In the 1960's, Homestake Mining Company collared diamond drill hole # 6091A at the western fringe of the Maitland Mine and drilled at a -50-degree angle to the southwest across Dakota Territory's recent land acquisition.

The hole was drilled to a total depth of 137.5 meters. This includes an 11.3-meter-long intercept from 111.2 meters to 122.5 meters down hole containing 5.18 grams per tonne gold.  The gold intercept in diamond drill hole #6091A was in the Precambrian Poorman - Homestake - Ellison stratigraphic sequence, which hosted the 40 million-ounce Homestake gold deposit situated just over 4 km to the south.

Dakota Territory Resource Corp. (DTRC), closed Friday's trading session at $0.054, up 0.19%, on 25,602 volume with 5 trades. The average volume for the last 60 days is 5,643 and the stock's 52-week low/high is $0.023/$0.10.

PEN, Inc. (PENC)

DreamTeamNetwork, SmallCapVoice, and Outcast Traders reported previously on PEN, Inc. (PENC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

PEN, Inc. is a global leader in developing, commercializing, and marketing enhanced-performance products enabled by nanotechnology. PEN stands for Products Enabled by Nanotechnology.  Products from its family of companies are for healthcare to homecare, homeland defense to food security, and transportation to recreation. PEN is headquartered in Miami, Florida.

PEN’s Applied Nanotech, Inc. subsidiary is in Austin, Texas. It functions as the Design Center conducting contract services for government and private customers and new product development for PEN focusing on unique and advanced product solutions in the areas of safety, health, and sustainability.

PEN is the combination of Nanofilm, Ltd. and Applied Nanotech Holdings, Inc. These are two nanotechnology innovators. PEN established to channel the potential of nanotechnology in real-world products for real-world users. With the combination of these two companies, PEN provides nano-layer coatings, nano-based cleaners, and nano-composite products.

PEN, by way of its wholly-owned subsidiary PEN Brands LLC (previously Nanofilm Ltd.), develops, manufactures, and sells products based on nanotechnology. This includes its Ultra Clarity® brand eyeglass cleaner, CLARITY DEFOG IT™ brand defogging products, CLARITY ULTRASEAL® nanocoating products for glass and ceramics, and an environmentally friendly surface protector, fortifier, and cleaner.

This week, PEN reported financial results for Q2 ended June 30, 2017. For the three months ended June 30, 2017, total Revenues were $2,002,609, versus revenues of $2,209,828 in the comparable period in 2016. For Q2 of 2017, overall Gross Profit amounted to $656,257, versus $793,086 for Q2 of 2016. Gross margin was 33 percent, versus 36 percent in the prior year period. Operating Loss was $363,570 in Q2 of 2017, versus an operating loss of $219,024 in Q2 of 2016.

PEN generated a loss for the quarter, mainly because of expenses associated with the upcoming relocation of its Product segment operations. However, the Company generated positive cash flow from operations during the quarter.

Mr. Scott Rickert, PEN's President, Chairman and Chief Executive Officer, said: "The second quarter was an active one at PEN. We commenced the relocation of our Ohio operations to a smaller facility nearby, a move that will allow us to outsource a good portion of our manufacturing and lower our cost structure while providing the flexibility to quickly meet the diverse and dynamic packaging needs of our customers. More importantly, it will allow PEN to focus on our primary mission of building a consumer products company offering compelling products enabled by nanotechnology. We are preparing for upcoming relaunch of our key health and safety products, including our environmentally friendly surface protector, which we expect to kick off in the fourth quarter once the relocation is complete.”

PEN, Inc. (PENC), closed Friday's trading session at $1.00, up 40.85%, on 16,410 volume with 16 trades. The average volume for the last 60 days is 2,235 and the stock's 52-week low/high is $0.71/$2.60.

graphic

The QualityStocks
Company Corner

graphic
graphic

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.86, off by 4.44%, on 60,079 volume with 58 trades. The stock’s average daily volume over the past 60 days is 45,697 and its 52-week low/high is $0.315/$2.75.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ChineseInvestors.com, Inc. (OTCQB: CIIX), a client of NNW recognizing unprecedented opportunities in the U.S. cannabis industry and laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products. The publication, titled, "Record Bitcoin Gains Indicate High Times Ahead for Cannabis Cryptocurrency," highlights the potential of the cryptocurrency industry, and the public companies operating within various niches of the market. To view the full publication, visit: https://www.networknewswire.com/industry-movers-riding-wave-bitcoins-increasing-value/

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

NetworkNewsWire Announces Publication Discussing the Monumental Impact of Bitcoin on the Cannabis Sector

ChineseInvestors.com, Inc. to Attend the Southern California Investment Forum and the MoneyShow San Francisco

ChineseInvestors.com, Inc. Announces the Launch of its Cryptocurrency Education and Trading Subscription Service on Chinesefn.com

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.7633, up 4.28%, on 279,573 volume with 173 trades. The stock’s average daily volume over the past 60 days is 66,643 and its 52-week low/high is $0.6171/$0.90.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

NetworkNewsWire Announces Publication Discussing Canadian Cannabis Investment Options

NetworkNewsWire Announces Publication on Canada's Top Cannabis Companies

NetworkNewsWire Announces Publication Discussing Public Companies Aiming to Take Advantage of Canada's Legal Marijuana Market

Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF)

The QualityStocks Daily Newsletter would like to spotlight Kootenay Zinc Corp. (KTNNF). Today, Kootenay Zinc Corp. closed trading at $0.07, up 14.57%, on 13,000 volume with 5 trades. The stock’s average daily volume over the past 60 days is 27,660, and its 52-week low/high is $0.0308/$0.59.

Kootenay Zinc Corp. (KTNNF) is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world's largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc's Sully project and Sullivan share many geological features:

  • Strata at Sully are in the same sedimentary basin as the Sullivan mine
  • The exact stratigraphic time horizon at which Sullivan formed is present at Sully
  • Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
  • Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
  • Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world's largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc's rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world's best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company's technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects. Disclaimer

Kootenay Zinc Corp. Company Blog

Kootenay Zinc Corp. News:

Sully Project - E3 Target Drilling Underway

Kootenay Zinc Corp.: Sully Project Exploration Update

NetworkNewsWire Releases Exclusive Audio Interview with Kootenay Zinc Corp. (KTNNF)

Algae Dynamics Corp. (ADYNF)

The QualityStocks Daily Newsletter would like to spotlight Algae Dynamics Corp. (ADYNF). Today, Algae Dynamics Corp. closed trading at $0.12, up 9.09%, on 17,500 volume with 4 trades. The stock’s average daily volume over the past 60 days is 10,025 and its 52-week low/high is $0.0001/$0.62.

Algae Dynamics Corp. (ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company's product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market's attractiveness can be further realized when considering that the Canada's licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics' plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company's initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market. Disclaimer

Algae Dynamics Corp. Blog

Algae Dynamics Corp. News:

Algae Dynamics Corp Enters Into a Letter of Intent with Bonify to Produce Unique Cannabis Oil Products; Accelerates Go-to-Market Strategy

NetworkNewsWire Releases Exclusive Audio Interview with Algae Dynamics Corp. (ADYNF)

Algae Dynamics Corp. (ADYNF) Engages NetworkNewsWire for Corporate Communications Solutions

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.237, up 1.72%, on 114,322 volume with 77 trades. The stock’s average daily volume over the past 60 days is 323,205, and its 52-week low/high is $0.06/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Announces Appointment of Creative Capital Media

InMed Announces Publication in European Journal of Pain

InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

StockMarketWatch
(DMTX) +162.50%

2.

QualityStocks
(PENC) +40.85%

3.

Barchart
(ADMS) +40.06%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251